PAN-90806
CAS No. 252003-65-9
PAN-90806 ( CP-547632 | CP547632 )
产品货号. M13744 CAS No. 252003-65-9
PAN-90806 (CP-547632, CP547632) 是一种高效、ATP 竞争性、口服活性的 VEGFR-2 抑制剂,可阻断 VEGFR-2 激酶自身磷酸化 (IC50=11 nM) 和 VEGF 诱导的 VEGFR-2 磷酸化 (IC50=5)纳米)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥680 | 有现货 |
|
| 10MG | ¥1077 | 有现货 |
|
| 25MG | ¥2211 | 有现货 |
|
| 50MG | ¥4277 | 有现货 |
|
| 100MG | ¥6221 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称PAN-90806
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PAN-90806 (CP-547632, CP547632) 是一种高效、ATP 竞争性、口服活性的 VEGFR-2 抑制剂,可阻断 VEGFR-2 激酶自身磷酸化 (IC50=11 nM) 和 VEGF 诱导的 VEGFR-2 磷酸化 (IC50=5)纳米)。
-
产品描述PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM); is approximately equipotent (<10-fold) against VEGFR-2, bFGF receptor and EGFR/Tie-2 chimera, 250-1000-fold selectivity over PDGFRβ, EGFR and InsR; inhibits tumor-associated VEGFR-2 phosphorylation with decreased microvascular density and significant tumor growth inhibition in a number of tumor models.
-
体外实验CP-547632 (1-1000 nM; 1 hours) inhibits VEGF-stimulated VEGFR-2 phosphorylation in a dose-dependent fashion, with an IC50 value of 6 nM. Western Blot Analysis Cell Line:Serum-deprived cells Concentration:1, 4, 16, 63, 250, 1000 nM Incubation Time:1 hours Result:Inhibited VEGF-stimulated VEGFR-2 phosphorylation in a dose-dependent fashion.
-
体内实验CP-547632 (p.o.; 6.25-100 mg/kg/day; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts. CP-547632 (oral; 50 mg/kg; a single oral dose) yieldes plasma concentrations above 500 ng/ml for 12 hours. Animal Model:Athymic female mice (CD-1 nu/nu) bearing tumors (75-150 mm in size)Dosage:6.25, 12.5, 25, 50, 100 mg/kg Administration:PO; daily; 10-24 days Result:Caused a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.Animal Model:Female athymic mice bearing H-Ras tumor Dosage:50 mg/kg Administration:Oral Result:A single oral dose of 50 mg/kg yielded plasma concentrations above 500 ng/ml for 12 hours.
-
同义词CP-547632 | CP547632
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR
-
研究领域Other Indications
-
适应症Other Disease
化学信息
-
CAS Number252003-65-9
-
分子量532.4
-
分子式C20H24BrF2N5O3S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (187.83 mM)
-
SMILESO=C(C1=C(NC(NCCCCN2CCCC2)=O)SN=C1OCC3=C(F)C=C(Br)C=C3F)N
-
化学全称3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Beebe JS, et al. Cancer Res. 2003 Nov 1;63(21):7301-9.
2. Cohen RB, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9.
021-51111890
购物车()
sales@molnova.cn

